Narjust Florez, Co-Director of Young Lung Cancer Program at Dana-Farber Cancer Institute, shared a post by International Association for the Study of Lung Cancer on LinkedIn, adding:
“Excellent discussion on the recent approval of subcutaneous amivantamab. This is a meaningful step forward-shorter administration time with maintained efficacy has real implications for patient experience and clinic workflow. Grateful for conversations that focus not only on innovation, but on how it truly impacts patients in daily practice.”
Quoting IASLC‘s post:
“New episode of Lung Cancer Considered!
This episode explores the FDA approval of subcutaneous amivantamab and its implications for modern oncology care.
Host Dr. Narjust Florez M.D. FASCO sits down with Dr. Natasha Leighl and Dr. Federico Cappuzzo to examine the underlying science, workflow and convenience considerations, and what this development means for patients, clinicians, and oncology practices moving forward. Listen now.”
More posts featuring Narjust Florez and IASLC on OncoDaily.